All patients are enrolled in Curalogic's clinical EU phase III trial with the ragweed product

Announcement no. 13/2007                                                        


To OMX the Nordic Exchange	                                 Copenhagen, June 6, 
2007                                                                            





All patients are enrolled in Curalogic's clinical EU phase III trial with the   
ragweed product                                                                 

Summary: Curalogic has completed the enrolment of patients into the EU phase III
clinical trial (RPE 04) with their product for treatment of ragweed allergy. A  
total of 545 patients have been enrolled into the trial. Patients will be       
treated until November 2007. Curalogic plans to report top line results from the
trial in the first quarter of 2008.                                             
                                                                                
The market for Curalogic's ragweed product is large, as there are approximately 
4 million people in Europe and 29 million people in the USA who suffer from     
ragweed allergy. Patients report ragweed allergy as being one of the worst      
pollen allergies                                                                

In 2007, Curalogic is conducting a clinical EU phase III trial (RPE 04) with the
ragweed product. The enrolment of patients started March 11, 2007, and continued
until June 4, 2007. Curalogic enrolled a total of 545 patients across USA,      
Italy, Hungary and Serbia. The ragweed pollen season starts in the middle of    
August, which means that all patients in the RPE 04 study will have a minimum of
10 weeks of treatment before the season.                                        

Peter Moldt, CEO of Curalogic said: ”It is a major milestone for Curalogic, that
we have had a good start with the ragweed trial and that we have the necessary  
number of patients enrolled in our first phase III clinical trial. The start of 
a multinational phase III trial of this magnitude is a very challenging task,   
which the Curalogic team has managed in a competent manner. The achievement of  
this milestone is validating Curalogic's business model, where the activities   
are conducted through outsourcing to external collaborators, under the guidance 
of a small internal team of experienced drug developers.”                       

Design of the clinical EU phase III trial                                       
The RPE 04 trial is a randomized, double-blind, placebo-controlled trial. The   
purpose of the trial is to evaluate the efficacy and safety of daily doses of   
ragweed pollen extract administered orally to patients who are allergic to      
ragweed. Dr. Peter Creticos, Medical Director of the Johns Hopkins Asthma and   
Allergy Center, is the principal investigator in the RPE 04 trial.              

Patients with moderate to severe ragweed allergy will be treated daily with an  
active dose or placebo. The active dose has in a previous trial, shown a similar
reduction in allergy symptoms to the reduction that is achieved with injection  
immunotherapy. The patients will take the pill at home and are not required to  
be under medical supervision. Treatment has been started prior to the ragweed   
pollen season and will continue throughout the entire season. Curalogic is      
expecting to report top line results from the trial in the first quarter of     
2008, and plans to submit an application for registration in Europe in the      
second half of 2008.                                                            


Yours sincerely,                                                                

Curalogic A/S                                                                   


For additional information, please contact:                                     
Peter Moldt, President and CEO, 	Phone +45 33 11 41 01, mobile +45 26 25 04 22  
Helle Busck Fensvig, EVP and CFO, 	Phone +45 33 11 41 01, mobile +45 20 70 55 37
About Curalogic                                                                 
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic        
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the        
treatment of allergy. By combining the best of two worlds - the efficacy of     
immunotherapy and with the safety and patient convenience of symptomatic        
treatments - Curalogic aims to develop a novel and user-friendly form of allergy
treatment, and make it the preferred type of allergy treatment among patients.  
Curalogic has a broad and mature pipeline with a product for treatment of       
ragweed allergy in Phase III, a product for treatment of grass allergy ready for
Phase III, a product for treatment of cat allergy in Phase II and a product for 
treatment of house dust mite allergy preparing for clinical trials.             











































This announcement contains forward-looking statements regarding the company's   
future financial development and performance and other statements which are not 
historical facts. Such statements are made on the basis of assumptions and      
expectations which, to the best of the company's knowledge, are reasonable at   
this time, but may prove to be erroneous in the future.